Projekt

BMS CA224-104 Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemothera-py vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Laufend - Rekrutierung – laufend · 2021 bis 2025